Vizora日本語

Japan Tissue EngineeringJapan Tissue Engineering Co., Ltd.7774東証グロース精密機器FY ending Mar 2026, non-consolidated, J-GAAP

Japan Tissue Engineering FY ending Mar 2025 results

About 55% of Japan Tissue Engineering's sales come from Regenerative Medicine Business, with Custom Development and Manufacturing Business and LabCyte Business making up much of the rest.

It lost about ¥10 for every ¥100 of sales at the operating level.

Revenue changed -2.3% from the prior year, operating profit -264.9%.

Revenue and profit pattern

Turned to a loss

What changed from last year

FY ending Mar 2024 → FY ending Mar 2025

Revenue
-2.3%¥2.51B → ¥2.46B
Gross profit
-10.6%¥1.69B → ¥1.51B
Operating income
-264.9%¥144.5M → -¥238.3M
Operating cash flow
-154.1%¥274.1M → -¥148.4M
Free cash flow
-25925.1%¥938K → -¥242.2M

Where the money goes

FY ending Mar 2024 → FY ending Mar 2025

※ Segment revenues include inter-segment sales and are scaled to consolidated revenue

Where ¥100 of sales goes

For every ¥100 Japan Tissue Engineering sells, how much goes where, and how much is kept.

FY ending Mar 2025
Cost of sales
¥39
SG&A
¥71
Operating loss
¥10
Net loss
¥10

Annual margin trends

Gross margin61.5%
FY ending Mar 2020: 51.4%51.4%FY ending Mar 2021: 51.2%51.2%FY ending Mar 2022: 59.7%59.7%FY ending Mar 2023: 55.9%55.9%FY ending Mar 2024: 67.2%67.2%FY ending Mar 2025: 61.5%61.5%FY20FY21FY22FY23FY24FY25
Operating margin-9.7%
FY ending Mar 2020: -10.2%-10.2%FY ending Mar 2021: -20.7%-20.7%FY ending Mar 2022: -23.7%-23.7%FY ending Mar 2023: -35.8%-35.8%FY ending Mar 2024: 5.7%5.7%FY ending Mar 2025: -9.7%-9.7%FY20FY21FY22FY23FY24FY25
Net margin-10.4%
FY ending Mar 2020: -12.4%-12.4%FY ending Mar 2021: -20.7%-20.7%FY ending Mar 2022: -23.7%-23.7%FY ending Mar 2023: -35.9%-35.9%FY ending Mar 2024: 5.7%5.7%FY ending Mar 2025: -10.4%-10.4%FY20FY21FY22FY23FY24FY25

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2025

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第28期(2025/04/01－2026/03/31)

    ID S100YDBW2026-06-18Open

  • EDINET (FSA Japan)

    有価証券報告書－第27期(2024/04/01－2025/03/31)

    ID S100VZSY2025-06-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第26期(2023/04/01－2024/03/31)

    ID S100TNDE2024-06-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第25期(2022/04/01－2023/03/31)

    ID S100QY5M2023-06-15Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第24期(2021/04/01－2022/03/31)

    ID S100Q2J82023-02-03Open

  • EDINET (FSA Japan)

    有価証券報告書－第23期(令和2年4月1日－令和3年3月31日)

    ID S100LOU72021-06-25Open

Extracted from XBRL: 43 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image